Key result
Cardiac syndrome X correlates with ~20% higher platelet-to-lymphocyte ratio versus healthy controls.
Why the study?
Is the platelet-to-lymphocyte ratio elevated in patients with cardiac syndrome X compared to healthy controls?
Case-Control (n=200)
No
Is the platelet-to-lymphocyte ratio elevated in patients with cardiac syndrome X compared to healthy controls?
Absolute Event Rate: 260% vs 217%
p-value: p=0.04
The platelet-to-lymphocyte ratio is significantly elevated in patients with cardiac syndrome X and may serve as a useful, low-cost biomarker for its evaluation.
Elevated PLR in cardiac syndrome X is hypothesis-generating; prospective validation required before biomarker consideration.
Objective: Cardiac syndrome X consist of anginal-like typical chest pain with positive cardiovascular stres test or presence of ischemia on myocardial perfusion scintigraphy but no flow-limiting stenosis on coronary angiography. The more likely pathophysiologic mechanisms for patients with cardiac syndrome X are subsequent microvascular ischemia, endothelial dysfunction and inflammation which may be the explanation of their anginal-like chest pain. Platelet to lymphocyte ratio is a potential biomarker for inflammation, and associated with endothelial dysfunction. We aimed to compare the role of platelet to lymphocyte ratio in patients with cardiac syndrome X and control subjects in this study. Method: The study group consist of 100 patients who underwent coronary angiography and were diagnosed as cardiac syndrome X according to the presence of exercise-induced typical angina pectoris and ischemia on myocardial perfusion scintigraphy with angiographically normal coronary arteries. For control subjects, we recruited 100 healthy gender- and age-matched individuals who were seen for health check-ups. Results: According to comparison of the hematological indices, mean value of the platelet to lymphocyte ratio in study population was higher than control group (260±16 vs 217±14, respectively; p=0.04)whereas the other hematological parameters did not differ between groups significantly. Conclusions: The platelet to lymphocyte ratio, which is easily calculated from routinely studied compete blood count and therefore requires no additional cost might be usefull for the evaluation of cardiac syndrome X based on the results of our study.
No takes yet. Share an insight, caveat, or question.
Hasan Ata Bolayır (2017) conducted a case-control in Cardiac syndrome X (n=200). Platelet-to-lymphocyte ratio (PLR) vs. Healthy controls was evaluated on Mean platelet-to-lymphocyte ratio (PLR) (p=0.04). The mean platelet-to-lymphocyte ratio was significantly higher in patients with cardiac syndrome X compared to healthy controls (260 vs 217, p=0.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: